Ritholtz Wealth Management’s Black Diamond Therapeutics BDTX Stock Holding History

Ritholtz Wealth Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$149K	Sell	79,183 -99,296	-56%	-$194K	﹤0.01%	1335
2026 Q2	$330K	Buy	178,479 +13,146	+8%	+$32.2K	﹤0.01%	1007
2026 Q1	$352K	Sell	165,333 -62,537	-27%	-$149K	0.01%	915
2025 Q4	$554K	Buy	227,870 +126,391	+125%	+$448K	0.01%	688
2025 Q3	$385K	Buy	+101,479	New	+$297K	0.01%	759

Other funds holding BDTX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Ritholtz Wealth Management's BDTX Position: Q3 2026 in Review

Ritholtz Wealth Management reduced its Black Diamond Therapeutics (BDTX) stake by 56% in Q3 2026, selling an estimated $194K and leaving 79,183 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #1335.

Ritholtz Wealth Management first reported a position in BDTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $554K in Q4 2025. 77 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

Ritholtz Wealth Management held 79,183 shares of Black Diamond Therapeutics worth $149K as of Q3 2026.
Ritholtz Wealth Management sold 99,296 Black Diamond Therapeutics shares in Q3 2026, an estimated $194K.
Black Diamond Therapeutics made up ﹤0.01% of Ritholtz Wealth Management's portfolio in Q3 2026, its #1335 holding.
Ritholtz Wealth Management first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 5 quarters since.
Ritholtz Wealth Management's Black Diamond Therapeutics position peaked at $554K in Q4 2025.
77 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on Ritholtz Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.